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Lower limb vasodilatory capacity is not reduced 
in patients with moderate COPD
Abstract: We compared exercise capacity (peak O2 uptake; V ·O2peak) and lower limb 
vasodilatory capacity in 9 patients with moderate COPD (FEV1 52.7 ± 7.6% predicted) and 
9 age-matched healthy control subjects. V ·O2peak was measured via open circuit spirometry 
during incremental cycling. Calf blood ﬂ  ow (CBF) measurements were obtained at rest and 
after 5 minutes of ischemia using venous occlusion plethysmography. While V ·O2peak was 
signiﬁ  cantly lower in the COPD patients (15.8 ± 3.5 mL·kg
–1·min
–1) compared with the control 
group (25.2 ± 3.5 mL·kg
–1·min
–1), there were no signiﬁ  cant differences between groups in peak 
CBF or peak calf conductance measured 7 seconds post-ischemia. V ·O2peak was signiﬁ  cantly 
correlated with peak CBF and peak conductance in the control group, whereas no signiﬁ  cant 
relationship was found between these variables in the COPD group. However, the rate of 
decay in blood ﬂ  ow following ischemia was signiﬁ  cantly slower (p < 0.05) for the COPD group 
(–0.036  ± 0.005  mL·100 mL
–1·min
–1·s
–1) when compared with controls (–0.048 ± 0.015 mL·
100 mL
–1·min
–1·s
–1). The results suggest that the lower peak exercise capacity in patients with 
moderate COPD is not related to a loss in leg vasodilatory capacity.
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Introduction
Chronic obstructive pulmonary disease is a major and increasing cause of disability 
in our aging population. Progressive damage to lung tissue is associated with 
increased shortness of breath on exertion leading to a “vicious cycle” of inactivity 
and worsening shortness of breath. While impaired lung mechanics is clearly the 
primary cause of disability in COPD patients, symptoms of leg fatigue are just as 
likely as breathlessness to cause these individuals to stop exercising (Killian et al 
1992). Exercise intolerance has been associated with changes in the peripheral 
muscle of patients with COPD. Prolonged physical inactivity and pathological 
dysfunction in the skeletal muscle of COPD patients are thought to decrease muscle 
mass and capillary density, alter muscle ﬁ  ber-type distribution, lower the activity 
of oxidative enzymes, and increase glycolytic enzyme activity (for a review, see 
Casaburi et al 1999). Although these morphological and biochemical changes 
contribute to exercise intolerance in patients with COPD, several studies indicate 
that muscle metabolism (and O2 utilization) per se may not be the primary factor 
limiting exercise capacity (Richardson et al 1999; Maltais et al 2001). Therefore, 
it is also possible that exercise capacity in COPD patients is limited by factors 
mediating muscle blood ﬂ  ow and O2 delivery to the active muscle.
The impact of COPD on blood ﬂ  ow and O2 delivery to the exercising muscle 
is not well understood. While there is some evidence to suggest that leg blood 
ﬂ  ow may not be limited at rest and during submaximal exercise in COPD patients 
(Maltais et al 1998), Simon et al (2001) have reported a plateau in lower limb International Journal of COPD 2006:1(1) 74
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blood ﬂ  ow during incremental exercise in some individuals 
with severe COPD. The inability to increase leg blood 
ﬂ  ow and O2 delivery in line with a rising metabolic rate 
may contribute to muscle fatigue and adversely affect 
exercise tolerance. One factor that could limit limb blood 
ﬂ  ow during exercise is a loss of vasodilatory capacity (as 
measured by peak blood ﬂ  ow or conductance following 
reactive hyperemia). Casiglia et al (1998) reported 
that peak hyperemic calf blood flow (CBF) was not 
signiﬁ  cantly different in patients with moderate-to-severe 
COPD when compared with control subjects. However, 
peak CBF in this study tended to be twice as high in the 
COPD patients as in the control subjects. Peak CBF in 
the control group was, in turn, approximately three times 
lower than previously published values (Kroese 1977a). 
Thus, while COPD patients with even mild-to-moderate 
levels of disease show a loss of exercise capacity, it is 
unclear what the effect of COPD (and associated physical 
inactivity) is on skeletal muscle vasodilatory capacity. 
In healthy older individuals, maximal or peak CBF and 
peak conductance are signiﬁ  cantly correlated with peak 
exercise capacity (peak O2 uptake; V ·O2peak), leading some 
researchers to suggest that the ability to regulate blood 
ﬂ  ow may be a limiting factor to exercise capacity in these 
individuals (Snell et al 1987; Martin et al 1991). Vasodilatory 
capacity has also been shown to increase with endurance 
training in young and older individuals (Martin et al 1990, 
1991). These studies demonstrate that an increase in physical 
activity could improve limb vasodilatory capacity. Based on 
the evidence presented, it may be that a reduction in V ·O2peak, 
secondary to a decline in physical activity, is accompanied by 
a loss in the maximum ability of the peripheral vasculature to 
increase muscle blood ﬂ  ow in patients with COPD.
To date, no study has examined the relationship between 
exercise capacity and lower limb CBF and conductance in 
patients with moderate COPD. The aim of this study was 
to compare exercise capacity and peak CBF responses in 
patients with moderate COPD. We hypothesized that patients 
with moderate COPD would have a lower V ·O2peak, peak 
CBF, and peak calf conductance than age-matched healthy 
subjects.
Methods
Subjects
Eighteen male subjects aged between 60 and 80 years 
volunteered to participate in this study: nine individuals with 
moderate COPD and nine healthy age-matched controls. 
Inclusion criteria for the COPD patients were moderate 
expiratory ﬂ  ow limitation as evidenced by FEV1 between 
80% and 30% of predicted values (Pauwels et al 2001), 
shortness of breath on exertion, and no documented history 
of substantial comorbidity. Diagnosis of COPD was 
based on a medical history questionnaire and pulmonary 
function test results. The control subjects were healthy non-
smokers with no current or past history of cardiopulmonary 
disorders. Subjects were excluded from the study if they 
were taking vasoactive medications that may have affected 
blood ﬂ  ow.
Experimental design 
All testing was performed in the Physiology of Exercise 
Research Laboratory, Gold Coast campus, Grifﬁ  th University, 
QLD, Australia. Subjects visited the laboratory on three 
separate occasions. During the ﬁ  rst visit, they underwent 
preliminary health screening and were familiarized with 
the methods to be used in the study. On the second visit, 
an incremental exercise test was performed on a cycle 
ergometer. The third and ﬁ  nal visit involved the measurement 
of CBF, calf volume, and percentage body fat. The study 
was approved by the Grifﬁ  th University Human Research 
Ethics Committee and all subjects provided written informed 
consent prior to their participation.
Pulmonary function and 
anthropometry 
Pulmonary function was measured and assessed using 
standard techniques (ATS 1994). FVC, FEV1, residual 
volume (RV), and diffusion capacity for carbon monoxide 
(DLCO) were measured using a Collins GS Modular 
Pulmonary Function Testing system (Braintree, MA, USA). 
Maximal voluntary ventilation (MVV) was estimated as 
FEV1 × 35 (Mohan-Kumar and Gimenez 1984). Disease 
severity was classified in accordance with The Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines (Pauwels et al 2001). 
To estimate percentage body fat, skinfold thickness 
was measured using a Harpenden skinfold caliper (Baty 
International, West Sussex, UK) at four sites on the upper 
body: biceps, triceps, subscapular, and suprailiac (Durnin 
and Womersley 1969). To obtain an estimate of leg adiposity, 
skinfold thickness of the anterior thigh and medial calf of the 
right leg was measured (ie, the leg in which blood ﬂ  ow and 
calf volume were determined). Calf volume was measured 
using a geometric method as described by Kaulesar Sukul 
et al (1993).International Journal of COPD 2006:1(1) 75
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Incremental exercise test 
The incremental exercise test used to measure V ·O2peak was 
performed on a Lode cycle ergometer (Excalibur Sport, 
Groningen, The Netherlands). Subjects began unloaded 
cycling for 3 minutes and then the power output was increased 
by 8 W·min–1 for the COPD group and by 15 W·min–1 for the 
healthy control group. Subjects were encouraged to maintain 
a pedal cadence of 60–70  rev·min–1 until volitional termination 
of the test.
Throughout the incremental cycling test, O2 uptake 
(V ·O2) and expired ventilation (V ·
E) were measured 
breath-by-breath and averaged over 30-second intervals 
using a metabolic measuring system (MedGraphics 
CPX/D, St Paul, MN, USA). A 12-lead ECG was used 
to monitor cardiac rhythm and to determine heart rate. 
Peak exercise values for incremental cycling were 
calculated as the average of the two highest consecutive 
30-second values obtained before termination of exercise. 
A medical practitioner supervised each incremental 
exercise test.
Calf blood ﬂ  ow and conductance 
CBF was measured using venous occlusion plethysmography 
(Whitney 1953). All blood ﬂ  ow tests were conducted at the 
same time in the morning in a quiet room with a constant 
ambient temperature between 23 and 24°C. Subjects fasted 
for 3 hours before the test and did not consume any caffeine 
or alcohol during the morning of the test. Additionally, all 
subjects refrained from strenuous exercise for 24 hours 
before the test.
Prior to the blood ﬂ  ow measurements, the subject was 
instructed to lie supine on a bed for 30 minutes. The right 
leg was elevated to the level of the heart by supporting the 
lower part of the leg (18 cm above and parallel to the bed) 
using a foam block under the knee and a strap supporting the 
foot. A 22-cm contoured thigh cuff was placed around the 
lower part of the thigh, just above the knee, and connected 
to a Rapid Cuff Inﬂ  ator (Hokanson E20, Bellevue, WA, 
USA). The foot was isolated from the circulation by a 5-cm 
cuff positioned around the ankle and inﬂ  ated to 240 mmHg. 
A mercury-in-rubber strain gauge was placed around the 
calf at the point of greatest girth. The strain gauge was inter-
faced to a computer via a Biopac Data Acquisition System 
(AcqKnowledge software, Biopac Systems Inc, CA, USA). 
The signal from the strain gauge was sampled at 100 Hz and 
ﬁ  ltered using a Hanning 3-Hz low-pass ﬁ  lter. 
Baseline CBF was recorded in two trials of 3 minutes’ 
duration. During each trial, the thigh cuff was intermittently 
inﬂ  ated to 60 mmHg (thereby permitting arterial inﬂ  ow of 
blood but occluding venous outﬂ  ow), in a duty cycle of 
30 seconds (15 seconds on and 15 seconds off). CBF 
was then determined by measuring the increase in calf 
circumference (ie, the initial slope of the signal recorded 
from the strain gauge) immediately after the cuff was 
inﬂ  ated (Siggaard-Anderson 1970). To avoid movement 
artifact, the ﬁ  rst second of the signal immediately after 
the cuff was inﬂ  ated was excluded from the analysis. 
The initial slope was then determined from the follow-
ing 3 seconds of data (Figure 1a). The mean value of at 
least six serial blood ﬂ  ow measurements was determined 
as baseline CBF per trial in milliliters per 100 mL calf 
volume per minute.
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Figure 1 (a) Plethysmograph tracing in a representative subject illustrating the 
hyperemic blood ﬂ  ow response following 5 minutes of arterial occlusion. The 
vertical dotted line (time 0 s) indicates the point when the cuff was released 
after 5 minutes of ischemia, with the ﬁ  rst blood ﬂ  ow measurement performed 7 
seconds after cuff release. The ﬁ  gure inset shows the slope of the initial increase 
in calf volume during a single venous occlusion cycle, from which calf blood ﬂ  ow 
is calculated. (b) Time course change in calf blood ﬂ  ow (CBF) immediately after 
arterial occlusion in healthy control subjects (open circles) and patients with 
COPD (ﬁ  lled circles). (c) Log-transformation of the blood ﬂ  ow versus time values 
presented in panel b. The slopes of the lines of best ﬁ  t represent the rates of decay 
in CBF. Only the ﬁ  rst 90 seconds of data (ie, the period when CBF was decreasing 
in both groups) was included in this analysis. The data in panels b and c represent 
mean values ± SD.International Journal of COPD 2006:1(1) 76
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Peak CBF was determined after two successive 5-minute 
periods of arterial occlusion, which were induced by inﬂ  ating 
the thigh cuff to a pressure of 220 mmHg (Chiba et al 1997). 
A resting period of 15 minutes was permitted between the two 
successive ischemic periods to ensure blood ﬂ  ow had returned 
to baseline (Siggaard-Anderson 1970; Proctor et al 2005). 
Immediately after the 5-minute period of arterial occlusion, 
12 serial blood ﬂ  ow measurements were recorded over a 
period of 3 minutes by intermittently inﬂ  ating the thigh cuff 
to a pressure of 80 mmHg (Marchiori et al 1994). To moni-
tor reactive hyperemic blood ﬂ  ow over time, a duty cycle of 
15 seconds was used (8 on, 7 off), as previously described 
(Chiba et al 1997). The ﬁ  rst blood ﬂ  ow measurement began 
7 seconds after the end of the arterial occlusion period, and 
peak CBF was accepted as the highest ﬂ  ow obtained during 
the successive measurements. All peak CBF measurements 
are also presented as a multiple of baseline CBF. In our 
laboratory, the day-to-day test-retest reliability (intra-class 
correlation coefﬁ  cient) for measuring resting and peak CBF 
was 0.95 and 0.96, respectively (n=10).
From each subject’s blood flow versus time curve 
(Figure 1b), the rate of decay in CBF (the slopes of the 
logarithmic function of blood ﬂ  ow versus time, illustrated 
in Figure 1c) was determined (Fry 1993). Excess blood ﬂ  ow 
was determined by calculating the area under the blood ﬂ  ow 
versus time curve minus baseline CBF for the duration of the 
3-minute post-ischemic measurement period.
During the measurement of baseline and post-ischemic 
CBF, heart rate and systolic and diastolic blood pressure 
were recorded using a Finapres (Ohmeda 2300 Finapres, 
Engelwood, CO, USA). The calculated mean arterial pressure 
(MAP) signal from the Finapres was recorded simultane-
ously with the strain gauge signal from the plethysmograph 
using the data acquisition software. Baseline and peak calf 
conductance were calculated from CBF and MAP:
  CBF (mL·100 mL–1·min–1)
Calf conductance =  ––––––––––––––––––––––   
 MAP  (mmHg)
post hoc adjustments. Pearson’s product-moment correlation 
coefficients were calculated to assess the relationships 
between blood ﬂ  ow measurements and V ·O2peak. Statistical 
signiﬁ  cance was accepted at p < 0.05.
Results
The physical characteristics of the subjects are presented 
in Table 1. The groups were well matched with respect to 
their physical characteristics. There were no signiﬁ  cant dif-
ferences between the groups in age, height, weight, blood 
pressure, calf volume, percentage body fat, or sum of the 
leg skinfolds. 
Pulmonary function test results for the two groups are 
presented in Table 2. Patients with COPD had signiﬁ  cantly 
lower FVC, FEV1, FEV1/FVC, MVV, and DLCO values than 
the control group. RV was signiﬁ  cantly greater in the COPD 
group. All lung function values for the control subjects were 
within the range of predicted values for healthy individuals 
of that age group (Knudson et al 1983). 
The results of the incremental exercise test are pro-
vided in Table 3. V ·O2peak was signiﬁ  cantly lower in the 
COPD group. The average peak power output achieved 
in the COPD group was only 42.8% of the peak power 
attained by the control group. Peak exercise heart rate 
was also signiﬁ  cantly lower in the COPD group. The 
control subjects reached 100.5% of their age-predicted 
maximum heart rate, whereas the patients with COPD 
reached only 79.8% of their predicted maximum. Peak 
exercise ventilation (V ·
Epeak), respiratory exchange ratio, 
and power output values were all signiﬁ  cantly lower in 
the COPD group. However, when V ·
Epeak was expressed 
as a percentage of MVV, no signiﬁ  cant difference was 
found between the two groups (p=0.84). The COPD group 
reached 84.1% of their estimated MVV, while the control 
group reached 85.9%. During the incremental cycling test, 
all subjects in the control group stopped exercise because 
of leg fatigue. In the COPD group, four subjects stopped 
exercise because of leg fatigue, two because of shortness 
of breath, and three from a combination of leg fatigue and 
breathlessness.
There were no significant differences between the 
two groups in resting (p=0.83) or peak CBF (p=0.85) 
(Figure 2a). The resting (COPD 3.8 ± 1.0 mL·100 mL–1·min–1; 
control 3.7 ± 1.4 mL·100 mL–1·min–1) and peak (COPD 
24.7 ± 6.5 mL·100 mL–1·min–1; control 25.5 ± 9.1 mL·100 mL  –1·min–1) 
CBF results in our study were similar to those reported in 
other studies that used similar methods of determining CBF in 
older individuals (Kroese 1977a, 1977b). Baseline and peak 
mL·100 mL–1·min–1·mmHg–1   (1)
Statistical analysis 
All results are presented as group means ± SD. Differences 
between groups in the dependent variables were determined 
using independent-sample t tests. The time-course change 
in hyperemic CBF was assessed using a 2-way repeated 
measures ANOVA (analysis of variance) with Bonferroni International Journal of COPD 2006:1(1) 77
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calf conductance were also not signiﬁ  cantly different between 
the COPD patients and healthy control subjects (Figure 2b). 
There were no signiﬁ  cant differences between the groups in 
peak CBF expressed as a function of resting CBF (peak CBF/
baseline CBF) (COPD 6.8 ± 1.8, control 7.3 ± 2.4; p=0.63). 
Similarly, the comparison of peak conductance as a function of 
resting conductance (peak conductance/baseline conductance) 
Table 1 Physical characteristics of the subjects (group means 
± SD)
  Control group  COPD group
Age (y)              71.7 ± 3.0             70.1 ± 6.1
Height (cm)            172.7 ± 4.8           170.4 ± 5.0
Body mass (kg)              80.9 ± 9.5             77.8 ± 8.3
Resting SBP (mmHg)            127.8 ± 13.9           128.0 ± 9.5
Resting DBP (mmHg)              75.6 ± 5.8             77.4 ± 6.3
Body fat (%)              21.4 ± 2.8             22.5 ± 4.1
Sum of leg skinfolds (mm)              22.4 ± 8.2             24.4 ± 8.8
Calf volume (L)              2.25 ± 0.34             2.18 ± 0.28
Abbreviations: DBP, diastolic blood pressure (supine); SBP, systolic blood pres-
sure (supine).
Table 2 Pulmonary function test results (group means ± SD)
  Control group  COPD group
FVC (L)               4.08 ± 0.67              3.45 ± 0.61a
FVC (% predicted)             111.0 ± 12.7              96.1 ± 13.4a
FEV1 (L)               3.05 ± 0.59              1.48 ± 0.29b
FEV1 (% predicted)             106.0 ± 20.3              52.2 ± 7.6b
FEV1/FVC (%)               74.8 ± 7.1              43.4 ± 7.3b
FEV1/FVC (% predicted)               94.3 ± 8.8              54.4 ± 8.9b
MVV (L·min–1)             106.7 ± 20.7              52.0 ± 10.0b
RV (L)               3.33 ± 0.59              4.06 ± 0.69a
RV (% predicted)             135.1 ± 22.9            171.7 ± 26.7a
DLCO (mL·min–1·mmHg–1)               21.0 ± 3.6              12.4 ± 5.8b
DLCO (% predicted)               86.9 ± 14.9              50.6 ± 22.9b
a p<0.05 vs control group.
b p<0.001 vs control group.
Abbreviations: DLCO, diffusion capacity for carbon monoxide; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; MVV, maximal voluntary 
ventilation; RV, residual volume.
Table 3 Peak exercise values obtained during incremental 
cycling (group means ± SD)
  Control group  COPD group
V ·O2peak (L·min–1)            2.04 ± 0.35            1.19 ± 0.24a
V ·O2peak (mL·kg–1·min–1)            25.2 ± 2.6            15.8 ± 3.5a
HRpeak (beats·min–1)             147 ± 16             118 ± 22b
HRpeak (% predicted)          100.5 ± 9.6            79.8 ± 12.3b
V ·
Epeak (L·min–1)            90.7 ± 18.7            42.8 ± 11.3a
Peak RER value            1.28 ± 0.07            1.06 ± 0.12a
Peak power (W)             166 ± 27               71 ± 23a
a p<0.0001 vs control group.
b p<0.01 vs control group.
Abbreviations: HRpeak, peak exercise heart rate; RER, respiratory exchange ratio;  
V ·
Epeak, peak minute ventilation;  V ·O2peak, peak O2 uptake.
was not signiﬁ  cantly different between the groups (COPD 
6.8 ± 1.9, control 7.6 ± 2.7; p=0.44). Figure 1b illustrates the 
time-course changes in CBF in both groups. CBF attained 
its peak value at the ﬁ  rst measurement point, 7 seconds 
after cuff release, and then decreased signiﬁ  cantly in both 
groups during the ﬁ  rst 90 seconds of the 3-minute measure-
ment period. Thereafter, CBF returned to baseline values, 
with no further decrease observed in either group. Although 
there were no signiﬁ  cant differences in CBF between the 
groups at any measurement period, the rate of decay in 
CBF was signiﬁ  cantly slower in the COPD group (–0.036
 ± 0.005 mL·100 mL–1·min–1·s–1) than in the control group
(–0.048 ± 0.015 mL100·mL–1·min–1·s–1) (Figure 1c). However, 
excess ﬂ  ow above baseline measured during the hyperemic 
period was not signiﬁ  cantly different between the groups 
(COPD 8.3 ± 2.0 mL·100 mL–1, control 7.5 ± 3.0 mL·100 mL–1; 
p=0.53). 
In the control group, V ·O2peak (L·min–1) was signiﬁ  cantly 
correlated with both peak CBF (Figure 3c) and peak conduct-
ance (Figure 3d), whereas there was no signiﬁ  cant relation-
ship between V ·O2peak and peak CBF or peak conductance 
observed in the COPD group (Figure 3a, 3b). Peak CBF 
was not signiﬁ  cantly correlated with V ·
Epeak or peak heart rate 
in either group.
Discussion
This is the ﬁ  rst study to examine the relationship between 
peak CBF responses and V ·O2peak in patients with moderate 
COPD. Although COPD patients had a much lower V ·O2peak 
than age-matched healthy controls, there was no difference 
between the groups in resting or peak CBF and conductance. 
Moreover, the signiﬁ  cant positive correlation between either 
peak CBF or peak conductance and V ·O2peak observed in the 
healthy older subjects was not seen in the COPD group.
V ·O2peak and the peak power achieved during incremental 
cycling were markedly lower in the COPD group than in 
healthy controls. Seven of the subjects in the COPD group 
stopped exercise because of leg fatigue or a combination of 
leg fatigue and breathlessness, whereas only two subjects 
stopped because of shortness of breath alone. Moreover, 
both groups reached a similar V ·
Epeak as a percentage of MVV 
(84.1% for the COPD group versus 85.9% for the control 
group) during incremental cycling. Since peak exercise 
heart rate was signiﬁ  cantly lower in COPD patients (79.8% 
of age-predicted maximum) than in healthy control subjects 
(100.5% of age-predicted maximum), we conclude that the 
patients in the present study did not experience a central 
cardiovascular limitation to exercise. Rather, lower limb International Journal of COPD 2006:1(1) 78
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muscle fatigue and dyspnea were the primary reasons for 
stopping exercise.
The only other study to examine CBF responses in COPD 
patients with strain-gauge plethysmography reported that 
subjects with mild-to-severe COPD had signiﬁ  cantly greater 
resting CBF, but similar peak CBF when compared with con-
trol subjects (Casiglia et al 1998). When the COPD group was 
further differentiated into those with mild obstruction (FEV1 
78.9 ± 5.6% predicted) and those with more severe obstruction 
(FEV1 49.2 ± 17.6% predicted), it was revealed that only those 
with severe disease had signiﬁ  cantly higher resting CBF than 
healthy control subjects. While the authors concluded that pa-
tients with COPD tended to be chronically vasodilated when 
compared with healthy controls, their results suggest that this 
statement applies only to subjects with more severe obstruc-
tion. The resting CBF results of the present study disagree 
with those of Casiglia et al (1998). We found that in a group 
of COPD patients with a comparable degree of expiratory 
ﬂ  ow limitation (FEV1 52.2 ± 7.6% predicted) to the subjects 
examined in their study, resting CBF was not signiﬁ  cantly 
different from that of healthy control subjects.
In the present study, we hypothesized that peak CBF 
would be lower in the COPD group than in the control group. 
However, our results suggest that the ability to maximally 
vasodilate the calf muscle vasculature has not been lost in 
individuals with moderate COPD. The hyperemia that fol-
lows ischemia (induced by arterial occlusion) is thought to 
arise from a combination of myogenic relaxation of blood 
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Figure 2 Baseline and peak calf blood ﬂ  ow (CBF) (a) and conductance (b) responses in healthy control subjects (open bars) and patients with COPD (ﬁ  lled bars). The 
data represent mean values ± SD.
vessels and the accumulation of locally released vasoactive 
metabolites (eg, prostaglandins, nitric oxide, K+, and H+) 
during the ischemic period (Shepherd 1983). Evidence sug-
gests that the loss of myogenic tone and hypoxia-induced 
vasodilator-prostaglandin synthesis contribute primarily to 
the peak ﬂ  ow response (Carlsson et al 1987; Engelke et al 
1996; Win and Marshall 2005). Additionally, prostagland-
ins, nitric oxide, and possibly other vasoactive metabolites 
such as adenosine mediate the remainder of the hyperemia 
response (Carlsson et al 1987; Tagawa et al 1994), as blood 
ﬂ  ow progressively returns to baseline. Since resting and peak 
CBF were not different between COPD patients and healthy 
control subjects, our results suggest that the factors mediating 
the hyperemic response observed in the present study are not 
affected by moderate lung disease.
Another factor that has been shown to affect the reactive 
hyperemic response is muscle mass. Wascher et al (1998) 
demonstrated that sex differences in forearm peak reactive 
hyperemic ﬂ  ow and excess ﬂ  ow could be accounted for 
primarily by differences in lean muscle mass between male 
and female subjects. Therefore, changes in vasodilatory ca-
pacity may occur only in more severe COPD, when cachexia 
is evident. In the present study, percentage body fat, calf 
volume, and skinfold thickness of the calf muscle were not 
signiﬁ  cantly different between COPD and healthy control 
groups. This suggests that lean muscle mass of the calf was 
not different between the two groups and could partly explain 
the similar blood ﬂ  ow results obtained in this study. International Journal of COPD 2006:1(1) 79
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The observation that peak CBF and conductance were 
signiﬁ  cantly correlated with V ·O2peak in healthy control sub-
jects, but not COPD patients, suggests that factors other 
than vasodilatory capacity limit exercise capacity in patients 
with COPD. However, this ﬁ  nding does not negate the pos-
sibility that impaired blood ﬂ  ow or O2 delivery contribute 
to skeletal muscle fatigue and exercise cessation in COPD 
patients. Abnormal ventilatory mechanics and dynamic lung 
hyperinﬂ  ation in COPD patients could increase the O2 cost 
of breathing during exercise, resulting in the redirection of 
blood ﬂ  ow from the active limb muscles to the respiratory 
muscles. The O2 cost of breathing is known to be greater for 
a given ventilatory demand in COPD patients than in healthy 
controls (Levison and Cherniack 1968). Moreover, a plateau 
in lower limb blood ﬂ  ow has been reported in some patients 
with severe COPD during incremental exercise (Simon et al 
2001). This ﬁ  nding suggests a respiratory “steal” of blood that 
may otherwise have been directed to the exercising muscles, 
and has also been observed in healthy athletes during intense 
exercise (Harms et al 1997). A reduction in muscle perfusion 
relative to metabolic demand may also occur as a result of 
a blunted cardiac output response to exercise, which has 
been reported in some COPD patients during incremental 
cycling (Bogaard et al 1998). Finally, reduced arterial O2 
Figure 3 Relationship between peak O2 uptake and peak calf blood ﬂ  ow, and peak O2 uptake and peak conductance in patients with COPD (a, b) and in healthy control 
subjects (c, d).
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content (hypoxemia) as a result of diffusion impairment or 
ventilation to perfusion inequalities in patients with COPD 
may adversely affect O2 diffusion across the capillary–muscle 
interface during periods of high metabolic demand. Studies 
have shown that O2 supplementation in COPD patients with 
varying degrees of hypoxemia enhances O2 delivery and 
muscle blood ﬂ  ow and increases V ·O2 and peak power output 
(Richardson et al 1999; Maltais et al 2001).
While we found no difference between the groups in peak 
CBF, the rate of decline in CBF (ie, duration of hyperemic 
ﬂ  ow) following ischemia was signiﬁ  cantly slower in COPD 
patients than in control subjects (Figure 1c). The magnitude 
of the hyperemic response (total excess ﬂ  ow) is dependent on 
peak ﬂ  ow when the period of ischemia is 5 minutes or less; 
when ischemia is imposed for longer periods, total excess 
ﬂ  ow is primarily affected by a longer duration of hyperemia, 
or a slower rate of decay in blood ﬂ  ow is observed (Patterson 
and Whelan 1955; Carlsson et al 1987; Wascher et al 1998). 
Thus, it is not clear what the slower rate of decay in peak 
CBF in COPD patients reﬂ  ects, considering that the duration 
of ischemia in the present study was 5 minutes and excess 
ﬂ  ow values were similar for both groups.
One could hypothesize that the slower fall in CBF (and 
calf conductance) reﬂ  ects a slower “washout” of metabolites 
following the period of ischemia or a greater accumulation of 
vasoactive metabolites during the ischemic period. Engelke 
et al (1996) hypothesized that the decay in blood ﬂ  ow following 
ischemia could be determined by the interaction between 
vasodilating and vasoconstricting prostaglandins. In COPD 
patients, urinary levels of prostaglandin-like compounds 
such as isoprostane F2α-III, a marker of oxidative stress, are 
greater than in healthy control subjects (Pratico et al 1998). 
These compounds could interact with locally produced pros-
taglandins during as well as after ischemia to affect the rate of 
blood ﬂ  ow decay. The selective loss of slow-twitch oxidative 
ﬁ  bers (Whittom et al 1998) and decreased activity of oxidative 
enzymes (Maltais et al 1996) in the skeletal muscles of COPD 
patients could also result in a greater and/or more prolonged 
efﬂ  ux of vasoactive metabolites (K+ and H+) into the circulation 
during the ischemic period. Alternatively, the difference in the 
rate of decay between the two groups may not be physiologically 
important despite attaining statistical signiﬁ  cance, since similar 
excess ﬂ  ow values were obtained for both groups. 
In summary, we tested the hypothesis that a reduced 
vasodilatory capacity would contribute to the diminished ex-
ercise capacity observed in COPD patients. Contrary to our 
hypothesis, we demonstrated that there were no differences in 
either baseline or peak CBF between patients with COPD and 
a group of age-matched, healthy controls. Moreover, peak CBF 
and conductance were signiﬁ  cantly correlated with V ·O2peak in 
the control subjects but not in the COPD patients. The results of 
this study show that vasodilatory capacity is not related to a loss 
of exercise capacity in patients with moderate COPD. Future 
studies should examine the effect of manipulating the duration 
of ischemia on total excess ﬂ  ow and the rate of blood ﬂ  ow decay, 
as well as the effect of disease severity and exercise training on 
reactive and functional hyperemia in COPD patients. 
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